Puretech Health's 15min chart shows Bollinger Bands Narrowing, KDJ Death Cross, Bearish Marubozu.

Puretech Health's 15-minute chart has exhibited a narrowing of Bollinger Bands, a KDJ Death Cross, and a Bearish Marubozu pattern on September 19, 2025, at 14:30. This suggests a decrease in the magnitude of stock price fluctuations, a shift in momentum towards the downside, and a potential for further decreases. The bearish momentum is likely to persist due to sellers dominating the market.

PureTech Health PLC (NASDAQ: PRTC) has shown several bearish signals on its 15-minute chart on September 19, 2025, at 14:30. The narrowing of Bollinger Bands, the KDJ Death Cross, and the Bearish Marubozu pattern indicate a decrease in the magnitude of stock price fluctuations, a shift in momentum towards the downside, and a potential for further decreases. These signals suggest that sellers are dominating the market, likely leading to a continuation of the bearish trend.

PureTech Health's stock price has been volatile, with a current price of $14.86, and a fifty-two week range between $13.30 and $24.99. The stock's fifty-day moving average is $17.79, and the two-hundred day moving average is $17.67. The company's fifty-two week low is $13.30, and the high is $24.99.

Institutional investors and hedge funds currently own 0.04% of PureTech Health shares. Notable new positions were established by Millennium Management LLC and Diadema Partners LP. Millennium Management acquired a new position worth $823,000 during the fourth quarter, while Diadema Partners LP acquired a new position worth $126,000 during the second quarter Short Interest in PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Rises By 24.5%^[1].

PureTech Health is developing LYT-100, a treatment for idiopathic pulmonary fibrosis (IPF), and LYT-200, an IgG4 monoclonal antibody targeting galectin-9 for treating solid tumors and hematological malignancies Short Interest in PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Rises By 24.5%^[1].

Verrica Pharmaceuticals (NASDAQ: VRCA), a dermatology therapeutics company, has recently announced that its development partner, Torii Pharmaceutical, received approval for YCANTH® (TO-208) in Japan for the treatment of molluscum contagiosum. This approval triggers a $10 million milestone payment to Verrica, strengthening its balance sheet with non-dilutive capital Verrica Pharmaceuticals Stock Price, News & Analysis^[2].